ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK ...
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
This episode features Athena Lendvay, the ERAS Program Coordinator at El Camino Hospital. Here, she discusses how El Camino Hospital got started with their ERAS program and the impact it has had on ...
Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Compared to ...
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback